INHIBIKASE THERAPEUTICS INC (IKT)
US45719W2052 - Common Stock
Overall IKT gets a fundamental rating of 3 out of 10. We evaluated IKT against 587 industry peers in the Biotechnology industry. The financial health of IKT is average, but there are quite some concerns on its profitability. IKT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year IKT has reported negative net income.
In the past year IKT has reported a negative cash flow from operations.
In the past 5 years IKT always reported negative net income.
In the past 5 years IKT always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -131.24%, IKT is doing worse than 84.96% of the companies in the same industry.
IKT has a worse Return On Equity (-173.42%) than 68.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -131.24% | ||
| ROE | -173.42% | ||
| ROIC | N/A |
ROA(3y)-79.46%
ROA(5y)-2911.53%
ROE(3y)-99.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IKT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IKT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IKT has more shares outstanding
IKT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for IKT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -8.42, we must say that IKT is in the distress zone and has some risk of bankruptcy.
IKT's Altman-Z score of -8.42 is on the low side compared to the rest of the industry. IKT is outperformed by 74.02% of its industry peers.
There is no outstanding debt for IKT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.42 |
ROIC/WACCN/A
WACC9.12%
2.3 Liquidity
IKT has a Current Ratio of 4.13. This indicates that IKT is financially healthy and has no problem in meeting its short term obligations.
IKT has a Current ratio (4.13) which is comparable to the rest of the industry.
IKT has a Quick Ratio of 4.13. This indicates that IKT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.13, IKT is in line with its industry, outperforming 47.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.13 | ||
| Quick Ratio | 4.13 |
3. Growth
3.1 Past
IKT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.36%, which is quite good.
Looking at the last year, IKT shows a very strong growth in Revenue. The Revenue has grown by 100.00%.
The Revenue for IKT have been decreasing by -42.21% on average. This is quite bad
EPS 1Y (TTM)17.36%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q40.74%
Revenue 1Y (TTM)100%
Revenue growth 3Y-28.07%
Revenue growth 5Y-42.21%
Revenue growth Q2Q-100%
3.2 Future
Based on estimates for the next years, IKT will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.77% on average per year.
IKT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 221.08% yearly.
EPS Next Y49.92%
EPS Next 2Y25.64%
EPS Next 3Y17.77%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y221.08%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for IKT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IKT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IKT's earnings are expected to grow with 17.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.64%
EPS Next 3Y17.77%
5. Dividend
5.1 Amount
IKT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INHIBIKASE THERAPEUTICS INC
NASDAQ:IKT (5/15/2024, 8:33:03 AM)
1.72
+0.18 (+11.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap11.15M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -131.24% | ||
| ROE | -173.42% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.13 | ||
| Quick Ratio | 4.13 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)17.36%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y49.92%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)100%
Revenue growth 3Y-28.07%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y